CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Heated chemo wash during surgery may stop stomach cancer spread
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal cancer from coming back in the belly lining. It is for 16 adults with high-risk cancer. The approach aims to kill any stray tumor cells that might …
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 05:25 UTC
-
Immunotherapy combo shows promise in esophageal cancer fight
Disease control TerminatedThis study tests whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer. About 278 adults with stage II to IVA cancer will receive the combination before and after s…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Virus-Enhanced treatment shows promise for Hard-to-Treat esophageal cancer
Disease control OngoingThis early-phase trial studies a new treatment for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. It combines a cancer-killing virus (OBP-301) with standard chemotherapy and radiation. The main goal is to check safety and find the best dose, w…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for stomach cancer: immunotherapy combo shows promise in genetic subtype
Disease control OngoingThis study tests whether the immunotherapy drug atezolizumab, alone or with chemotherapy, can shrink or control a specific type of stomach or gastroesophageal junction cancer that has a high number of genetic mutations (MSI-H/dMMR). About 240 adults with early-stage but resectabl…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New combo before surgery shows promise against esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC